Longeveron (LGVN) Change in Receivables (2020 - 2026)
Longeveron (LGVN) recorded quarterly Change in Receivables of -$36000.0 in Q1 2026, down 169.23% quarter-over-quarter from $52000.0 in Q4 2025, and up 34.55% on a YoY basis from -$26756.8 in Q1 2025.
Longeveron (LGVN) Change in Receivables (2020 - 2026) Analysis & Trends
Longeveron's Change in Receivables history runs 7 years deep, the most recent figure standing at -$36000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 34.55% year-over-year to -$36000.0; the TTM figure through Mar 2026 stood at $39000.0 (up 126.17% YoY), while the FY2025 annual figure was $20000.0, up 174.07% from the prior year.
- Change in Receivables was -$36000.0 for Q1 2026 at Longeveron, down from $52000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $162000.0 in Q3 2024 to a low of -$296000.0 in Q4 2024.
- Historically, Change in Receivables has averaged $933.33 across 5 years, with a median of $40000.0 in 2022.
- Biggest YoY gain for Change in Receivables was 154.92% in 2024; the steepest drop was 2073.33% in 2024.
- A 5-year view of Change in Receivables shows it stood at $42000.0 in 2022, then slumped by 64.29% to $15000.0 in 2023, then tumbled by 2073.33% to -$296000.0 in 2024, then soared by 117.57% to $52000.0 in 2025, then plunged by 169.23% to -$36000.0 in 2026.
- The last three Change in Receivables figures came in at -$36000.0 (Q1 2026), $52000.0 (Q4 2025), and $21000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36,000.00 |
| Mar 31, 2026 | -36,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -55,000.00 |
| Mar 31, 2025 | -55,000.00 |
| Dec 31, 2024 | -296,000.00 |
| Dec 31, 2024 | -296,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 15,000.00 |
| Dec 31, 2023 | 15,000.00 |